VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

January 20, 2010 08:00 ET

VentriPoint Announces Acceptance of Second Clinical Validation Study for Publication

SEATTLE, WASHINGTON--(Marketwire - Jan. 20, 2010) - VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT) is pleased to announce that The American Journal of Cardiology has accepted a second study describing work done by primary investigator Dr. Florence Sheehan at the University of Washington with collaborators from Europe and the United States. The study is to be published by the peer-reviewed journal in June 2010, following the previously announced publication of a study by Dr. Sheehan and her collaborators in The American Journal of Cardiology for the April 2010 issue. These studies further validate the breakthrough technology developed by Dr. Sheehan that has been incorporated into the VentriPoint Medical System. The technology is used to generate critical heart measurements in three dimensions from two-dimensional ultrasound images with significantly greater speed and accuracy and at a considerably lower cost than is otherwise possible.

"This study reported the error of the commonly-used Simpson's method when compared with 3D analysis using a Piecewise Smooth Subdivision Surface reconstruction method (PSSS) developed and patented by the University of Washington," said Dr. Sheehan, cardiologist and research professor at the University of Washington as well as chief scientist and co-founder of VentriPoint.

The VentriPoint Medical System (VMS) is the only product that utilizes the PSSS technology to create surface reconstructions of heart ventricles. This technology was developed by Dr. Florence Sheehan and is licensed exclusively to VentriPoint, Inc. The study demonstrates the advantage of 3D reconstructions of the right ventricle compared with the technology that is currently the standard of care in the treatment of patients with right heart disease. 

"VentriPoint is very proud of Dr. Sheehan's groundbreaking work in developing an easily-accessible tool for monitoring right ventricular volume and function," said Joe Ashley, president and CEO of the corporation. "Acceptance of this second study by The American Journal of Cardiology underscores the vital importance of this tool in improving the care of the more than 800,000 children and 1 million adults in the United States alone with congenital heart disease. This PSSS technology will be used in the VentriPoint Medical System as we expand this application to all heart diseases which affect the right ventricle, potentially aiding over 160 million people worldwide."

About VentriPoint Diagnostics Ltd. VentriPoint creates diagnostic tools to monitor patients with heart disease, the number one cause of death in developed countries. The VentriPoint Medical System is based upon technology licensed exclusively by VentriPoint from the University of Washington. The VMS is being adapted for a variety of heart-related diseases, with congenital heart disease representing the first application, and applications for pulmonary hypertension, cardiovascular disease and heart failure in process to follow. Canada and Europe have granted license approval for the VMS diagnostic tool, and VentriPoint anticipates responding to the U.S. Federal Drug Administration's 510(k) review in January.

To receive press release, please email and mention VentriPoint in the Subject line.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • VentriPoint Diagnostics
    Ed Garth
    Chief Financial Officer
    (206) 283-0221, ext. 402
    (206) 283-2309 (FAX)
    CHF Investor Relations
    Christopher Haldane
    Account Manager
    (416) 868-1079 ext.237
    (416) 868-6198 (FAX)